Saturday 20 Apr, 2024 12:07 PM
Site map | Locate Us | Login
   CRISIL upgrades rating of Tata Power's LT rating to 'AA+' with 'stable' outlook    IREDA Q4 PAT climbs 33% YoY to Rs 337 cr    HDFC AMC Q4 PAT climbs 44% YoY; recommends dividend of Rs 70/sh    Wipro Q4 PAT rises 5% QoQ to Rs 2,835 cr    Premier Explosives gains as board OKs 1:5 stock split    Hindustan Zinc slides after Q4 PAT decline 21% YoY    Axis Bank board to mull fund raising    Elecon Engg hits record high on strong Q4 outcome, board OKs 1:2 stock split    Jubilant Pharmova Ltd leads losers in 'A' group    Anmol India Ltd leads losers in 'B' group    Volumes soar at TVS Supply Chain Solutions Ltd counter    Information Technology shares slide    Auto stocks edge lower    Real Estate stocks slide    Aurionpro Solutions hits the roof on 67% acquisition in Arya.ai 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin gains on bagging US FDA nod for HIV treatment drug
04-Oct-22   13:21 Hrs IST

The approved abbreviated new drug application (ANDA) is a generic equivalent of Prezista Tablets of Janssen Products, LP.

Darunavir is an antiviral medicine that is used to treat HIV (human immunodeficiency virus). HIV can cause acquired immunodeficiency syndrome (AIDS).

Darunavir Tablets, 600 mg and 800 mg, (reference listed drug: Prezista) had estimated annual sales of $343 million in the U.S. (IQVIA MAT June 2022).

Lupin is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity. The company will also potentially have shared 180-day exclusivity on the 600 mg tablets.

The product will be manufactured at Lupin's facility in Nagpur, India,” the drug maker said in a statement.

Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The drug maker reported a net loss of Rs 89.1 crore in Q1 FY23 as against a net profit of Rs 542.5 crore in Q1 FY22. Total revenue from operations declined 12.3% YoY to Rs 3,743.8 crore during the quarter.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 32024144
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd